The estimated Net Worth of David C. Benedicto is at least 43.6 千$ dollars as of 18 March 2022. Mr Benedicto owns over 3,603 units of Adamis Pharmaceuticals Corp stock worth over 30,704$ and over the last 3 years he sold ADMP stock worth over 12,905$.
Mr has made over 2 trades of the Adamis Pharmaceuticals Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,603 units of ADMP stock worth 2,198$ on 18 March 2022.
The largest trade he's ever made was selling 13,554 units of Adamis Pharmaceuticals Corp stock on 1 December 2021 worth over 10,708$. On average, Mr trades about 8,579 units every 53 days since 2021. As of 18 March 2022 he still owns at least 39,875 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Mr Benedicto stock trades at the bottom of the page.
David C. Benedicto is the Chief Financial Officer at Adamis Pharmaceuticals Corp.
Mr Benedicto is 60, he's been the Chief Financial Officer of Adamis Pharmaceuticals Corp since . There are 8 older and 3 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
David's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300, SAN DIEGO, CA, 92130.
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over 2,051,720$ worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth 188,843$ . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho...、Dennis J Phd Carlo、David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of 12,919$. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth 192,500$.
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include: